Zanaflex, Tizanidine News

Jun 8, 2009 - Acorda Therapeutics, Inc. today announced that, in response to its eligibility application to the European Medicines Agency for Fampridine-SR, the EMEA has notified the Company that Fampridine-SR is eligible to be submitted for a Marketing Authorization Application via the Agency's Centralized Procedure.

Spasticity is a condition when certain muscles are continuously contracted. This contraction causes stiffness or tightness of the muscles and may interfere with movement, speech, and the way people walk.

May 6, 2009 - Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has accepted the Fampridine-SR New Drug Application for filing, assigning Priority Review and a Prescription Drug User Fee Act date of October 22, 2009.

HAWTHORNE, N.Y., Apr 29, 2009 -- --Greatest Changes in Income Level Due to Mobility Loss Occur Early On, as People with MS Transition from Normal Mobility to Minimal Mobility Impairment People with multiple sclerosis experience reduced income and earning potential as their mobility impairment increases, according to data collected from more than ...

Acorda Therapeutics, Inc. today announced the resubmission of its New Drug Application for Fampridine-SR to the U.S. Food and Drug Administration .

NEW YORK, Mar 19, 2009 -- New York's leading bioscience companies will present at the New York Bioscience Company Showcase, a new addition to the NYBA Annual Meeting.

Fampridine-SR Development Program The Fampridine-SR NDA submission is based on data from a comprehensive development program assessing the safety and efficacy of Fampridine-SR, including two Phase 3 trials that ...

"2008 was a year of exceptional achievement for Acorda. Our recent NDA filing for Fampridine-SR in MS follows the success of our second Phase 3 clinical trial, which was conducted under a special protocol ...

City police took a Bedford man into custody alleging he was stealing medication from a coworker.